Published in J Virol on June 01, 1994
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity. J Virol (1998) 3.23
Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J Virol (2002) 2.43
Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J Virol (2001) 2.42
Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization. J Exp Med (1997) 2.31
Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J Virol (1999) 2.23
Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. J Virol (2003) 1.84
Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J Virol (2004) 1.80
Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J Virol (2008) 1.71
Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6. J Virol (2001) 1.35
Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med (2006) 1.34
Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes. J Virol (2000) 1.34
Basic research in HIV vaccinology is hampered by reductionist thinking. Front Immunol (2012) 1.33
Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion. J Virol (2002) 1.30
HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities. J Virol (2014) 1.29
Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses. Virology (2008) 1.25
Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes. PLoS One (2009) 1.10
Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitors. Virology (2011) 0.98
Minimal incidence of serum antibodies reactive with intact primary isolate virions in human immunodeficiency virus type 1-infected individuals. J Virol (1999) 0.92
Neutralization interfering antibodies: a "novel" example of humoral immune dysfunction facilitating viral escape? Viruses (2012) 0.88
Topological analysis of HIV-1 glycoproteins expressed in situ on virus surfaces reveals tighter packing but greater conformational flexibility than for soluble gp120. J Virol (2013) 0.85
Synergy determination issues. J Virol (2002) 0.85
Excretion of human immunodeficiency virus type 1 through polarized epithelium by immunoglobulin A. J Virol (2008) 0.85
An Outdated Notion of Antibody Specificity is One of the Major Detrimental Assumptions of the Structure-Based Reverse Vaccinology Paradigm, Which Prevented It from Helping to Develop an Effective HIV-1 Vaccine. Front Immunol (2014) 0.82
Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives. Adv Biol (2014) 0.81
Antigenic variation within the CD4 binding site of human immunodeficiency virus type 1 gp120: effects on chemokine receptor utilization. J Virol (2001) 0.81
The W100 pocket on HIV-1 gp120 penetrated by b12 is not a target for other CD4bs monoclonal antibodies. Retrovirology (2012) 0.80
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul (1984) 35.22
Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci U S A (1988) 8.40
Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature (1992) 4.75
Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J Virol (1992) 4.72
Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to Gp120. Science (1991) 4.09
Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J Virol (1991) 3.93
Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. AIDS Res Hum Retroviruses (1987) 3.67
Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J Immunol (1993) 3.39
Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet (1988) 3.32
Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci U S A (1991) 2.85
Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res Hum Retroviruses (1991) 2.52
Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature (1991) 2.28
Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. J Acquir Immune Defic Syndr (1993) 2.14
Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro. Proc Natl Acad Sci U S A (1990) 2.08
Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120. AIDS Res Hum Retroviruses (1992) 1.94
Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120. AIDS Res Hum Retroviruses (1992) 1.85
Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120. Virology (1992) 1.84
Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus. J Gen Virol (1988) 1.83
Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J Immunol (1990) 1.68
Cooperativity of neutralizing antibodies directed against the V3 and CD4 binding regions of the human immunodeficiency virus gp120 envelope glycoprotein. J Acquir Immune Defic Syndr (1992) 1.57
Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains. AIDS Res Hum Retroviruses (1992) 1.53
Complement activation by human monoclonal antibodies to human immunodeficiency virus. J Virol (1993) 1.36
Topographical and functional mapping of epitopes on hog cholera virus with monoclonal antibodies. J Gen Virol (1989) 1.27
Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41. AIDS Res Hum Retroviruses (1993) 1.24
Synergistic inhibition of HIV-1 by CD4 binding domain reagents and V3-directed monoclonal antibodies. Virology (1993) 1.21
A rapid, automated microtiter assay for measuring neutralization of HIV-1. AIDS Res Hum Retroviruses (1993) 1.18
Anti-HIV-1 ADCC. AIDS Res Hum Retroviruses (1989) 1.05
Human monoclonal antibodies to the V3 loop of HIV-1 gp120 mediate variable and distinct effects on binding and viral neutralization by a human monoclonal antibody to the CD4 binding site. J Acquir Immune Defic Syndr (1993) 1.05
Epitope analysis of human cytomegalovirus glycoprotein complexes using murine monoclonal antibodies. Virology (1988) 0.99
Synergistic neutralization of rubella virus by monoclonal antibodies to viral haemagglutinin. J Gen Virol (1987) 0.94
Prevention of cytomegalovirus infection in bone marrow transplant recipients by prophylaxis with an intravenous, hyperimmune cytomegalovirus globulin. Birth Defects Orig Artic Ser (1984) 0.82
Two-year study of passive-active immunization for prevention of hepatitis B infection in newborns. J Med Assoc Thai (1988) 0.78
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood (1999) 11.57
Disseminated Kaposi's sarcoma in homosexual men. Ann Intern Med (1982) 4.98
Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science (1983) 4.72
Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J Virol (1992) 4.72
Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1. J Virol (1989) 4.07
Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J Virol (1991) 3.93
Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J Immunol (1993) 3.39
Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J Virol (1994) 3.33
Generation of human monoclonal antibodies to human immunodeficiency virus. Proc Natl Acad Sci U S A (1989) 3.07
Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology (1995) 3.06
Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol (1994) 2.96
Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci U S A (1991) 2.85
Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J Virol (1998) 2.83
Kinetics of expression of multiply spliced RNA in early human immunodeficiency virus type 1 infection of lymphocytes and monocytes. Proc Natl Acad Sci U S A (1991) 2.81
Immunologic abnormalities in homosexual men. Relationship to Kaposi's sarcoma. Am J Med (1982) 2.71
Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med (1995) 2.12
Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro. Proc Natl Acad Sci U S A (1990) 2.08
Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J Virol (1991) 2.00
Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J Virol (1999) 1.97
Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J Virol (2000) 1.96
Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120. AIDS Res Hum Retroviruses (1992) 1.94
Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity. J Immunol (1997) 1.89
Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry. J Virol (1995) 1.80
Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41. J Virol (2000) 1.78
Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. J Virol (1998) 1.75
Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J Immunol (1990) 1.68
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis (1998) 1.64
Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med (1997) 1.62
Identification of HIV vaccine candidate peptides by screening random phage epitope libraries. Virology (1993) 1.60
Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions. J Virol (1997) 1.59
Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines. J Infect Dis (1997) 1.57
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. Br J Cancer (2013) 1.57
Amino acid residues of the human immunodeficiency virus type I gp120 critical for the binding of rat and human neutralizing antibodies that block the gp120-sCD4 interaction. Virology (1992) 1.56
Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains. AIDS Res Hum Retroviruses (1992) 1.53
Kaposi's sarcoma in homosexual men. A seroepidemiologic case-control study. Ann Intern Med (1984) 1.50
Human B-lymphotropic virus (human herpesvirus-6). J Virol Methods (1988) 1.48
Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. Int Immunol (1997) 1.46
Human humoral responses to antigens of Mycobacterium tuberculosis: immunodominance of high-molecular-mass antigens. Clin Diagn Lab Immunol (1997) 1.43
Serodiagnostic potential of culture filtrate antigens of Mycobacterium tuberculosis. Clin Diagn Lab Immunol (2000) 1.39
Human immunodeficiency virus (HIV) envelope binds to CXCR4 independently of CD4, and binding can be enhanced by interaction with soluble CD4 or by HIV envelope deglycosylation. J Virol (1998) 1.39
Delineation of human antibody responses to culture filtrate antigens of Mycobacterium tuberculosis. J Infect Dis (1998) 1.36
Complement activation by human monoclonal antibodies to human immunodeficiency virus. J Virol (1993) 1.36
Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6. J Virol (2001) 1.35
Surrogate marker of preclinical tuberculosis in human immunodeficiency virus infection: antibodies to an 88-kDa secreted antigen of Mycobacterium tuberculosis. J Infect Dis (1997) 1.35
Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J Immunol (1994) 1.35
Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes. J Virol (2000) 1.34
Molecular studies of HHV-6. J Virol Methods (1988) 1.32
Quantitation of beta 2-microglobulin and other immune characteristics in a prospective study of men at risk for acquired immune deficiency syndrome. JAMA (1984) 1.32
Suppression of the humoral immune response by plasmacytomas: mediation by adherent mononuclear cells. J Immunol (1977) 1.31
Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain. Proc Natl Acad Sci U S A (1989) 1.31
Effects of oligomerization on the epitopes of the human immunodeficiency virus type 1 envelope glycoproteins. Virology (2000) 1.29
Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity. J Virol (1998) 1.28
A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. J Infect Dis (1999) 1.27
Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. AIDS Res Hum Retroviruses (1997) 1.26
Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus type 1. J Virol (2001) 1.26